Intranasal Immunization with Recombinant Hemagglutinin of Influenza A/H5 Virus Complexed with Novochizol Induces Virus-Neutralizing Antibodies and Protects Animals from Lethal Viral Challenge
Authors:
- Nadezhda B. RudometovaNadezhda B. Rudometova
- Ivanova K.I.Ivanova K.I.
- Vladislav V. FomenkoVladislav V. Fomenko
- Andrey P. RudometovAndrey P. Rudometov
- Lyubov A. KisakovaLyubov A. Kisakova
- Denis N. KisakovDenis N. Kisakov
- Elena V. TigeevaElena V. Tigeeva
- Vladimir A. YakovlevVladimir A. Yakovlev
- Makarova K.P.Makarova K.P.
- Vakhitov D.I.Vakhitov D.I.
- Mariya B. BorgoyakovaMariya B. Borgoyakova
- Ekaterina V. StarostinaEkaterina V. Starostina
Preprint
- 10 April 2026
- preprint
- Published by MDPI AG in Preprints.org
Abstract
Avian influenza is a critical zoonotic infection threatening both the poultry industry and global public health. While traditional intramuscular vaccines elicit systemic im-munity, they often fail to provide robust local protection at mucosal surfaces. There is thus significant interest in the development of mucosal avian influenza vaccines administered via the intranasal route. However, in humans, this approach is significantly hampered by the availability of safe and effective adjuvants. This study investigated the immunogenic-ity of a modified recombinant influenza A/H5 hemagglutinin (rHA/H5-modif) formulated with Novochizol, a novel chitosan-derived delivery system, administered intranasally to laboratory animals. Our results demonstrate that mucosal immunization with the rHA/H5-modif/Novochizol complex induces potent humoral (IgG and IgA) and cell-mediated immune responses. Crucially, the formulation provided 100% survival in mice following a lethal challenge with highly pathogenic avian influenza A/H5. These findings position the rHA/H5-modif/Novochizol complex as a promising candidate for next-generation mucosal vaccines, in particular against highly pathogenic avian influen-za A/H5 subtype.Keywords
All Related Versions
- Version 1, 2026-04-10, Preprints
- Published version: Pharmaceutics, 18 (6), 669.
This publication has 31 references indexed in Scilit:
- An intranasal adjuvanted, recombinant influenza A/H5 vaccine primes against diverse H5N1 clades: a phase I trialNature Communications, 2025
- An intranasal subunit vaccine induces protective systemic and mucosal antibody immunity against respiratory viruses in mouse modelsNature Communications, 2025
- A respiratory mucosal vaccine based on chitosan/aluminum adjuvant induces both mucosal and systemic immune responsesInternational Journal of Pharmaceutics, 2025
- Advances in intranasal vaccine delivery: A promising non-invasive route of immunizationVaccine, 2023
- Mucosal vaccines: Strategies and challengesImmunology Letters, 2020
- Influenza virus-specific CD4+ and CD8+ T cell-mediated immunity induced by infection and vaccinationJournal of Clinical Virology, 2019
- Globular chitosan prolongs the effective duration time and decreases the acute toxicity of botulinum neurotoxin after intramuscular injection in ratsToxicon, 2018
- Globular chitosan treatment of bovine jugular veins: evidence of anticalcification efficacy in the subcutaneous rat modelCardiovascular Pathology, 2018
- Innate immunity to influenza virus infectionNature Reviews Immunology, 2014
- Preexisting influenza-specific CD4+ T cells correlate with disease protection against influenza challenge in humansNature Medicine, 2012